explore -WSS

explore

author：Wikipedia 2025-09-27 19:37:15 - browse：38181

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： RSV shot was 90% effective at preventing hospitalizations in kids

WSS

Amylyx ALS drug fails large clinical trial

UnitedHealth quietly bought dozens of outpatient centers

Just how do doctors, lawmakers, and the public define abortion?

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

First medicine developed to treat MASH expected to be approved soon

Headspace, Meta partner to launch VR meditation app for Quest

focus

explore

entertainment

Tori Bowie and the unacceptable rates of Black maternal death

The stability of $0 premiums in Medicare Advantage

After affirmative action ruling, medical educators look to 'holistic review'

What will Novo Nordisk's VC do with its influx of cash?

In age of alternative facts, a scholarly course on calling out crap

Will an HIV vaccine ever be a reality?

How to save PrEP access — and even expand it

Congress extends some pandemic preparedness programs

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

hotspot

Setback for rare diseases as Taysha Gene Therapies pulls back

The United States is paying nearly triple for new Covid vaccines

The problem with charging patients to message their doctors

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Sen. Paul opposes bill to ban Chinese biotechs

Stop Congress from blocking public access to science

leisure time

hotspot

hotspot

explore